Cautious. BVS scores middling on both growth (49) and value (46), with a forward P/E of 15.6 offering no margin of safety for mediocre compounder traits. Leadership alignment is weak (55/100)—suggesting misaligned incentives or founder drift—while vulnerability sits at the threshold (50), with only an adequate financial buffer against downturns. Lack of clear competitive moat or exceptional returns on capital make this a pass unless fundamentals sharpen materially.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for Bioventus Inc.:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 50/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates Bioventus Inc. (BVS) at 50/100 — below the bar Stocky looks for. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Cautious. BVS scores middling on both growth (49) and value (46), with a forward P/E of 15.6 offering no margin of safety for mediocre compounder traits. Leadership alignment is weak (55/100)—suggesting misaligned incentives or founder drif
BVS's current Stocky Verdict is 50/100, placing it in the "Cautious" band. This composite combines a 49/100 Compounder score, 55/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for Bioventus Inc. yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
Bioventus Inc. scores 55/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
Bioventus Inc.'s Vulnerability Profile scores 50/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to Bioventus Inc..
Sign up free and unlock the full analysis on BVS — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
Or jump straight to the interactive dashboard for BVS in the app.
